Fortress Biotech Inc - Company Profile
Powered by 
All the sales intelligence you need on Fortress Biotech Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Fortress Biotech Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Fortress Biotech Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Fortress Biotech Inc (Fortress Biotech) is a biopharmaceutical company. It identifies and evaluates products and product candidates for potential acquisition. The company is involved in the development and commercialization of biopharmaceutical products through its subsidiaries and partner companies. Fortress Biotech’s product portfolio includes Qbrexza, Accutane, Amzeeq, and Zilxi, which are marketed by its partner company Journey Medical Corporation. These products are primarily used in dermatology for treating conditions such as hyperhidrosis, acne, and rosacea. The company has a product pipeline that includes candidates developed with partners in areas such as oncology, rare diseases, and gene therapy. Fortress Biotech is headquartered in Bay Harbor Islands, Florida, the US.
Headquarters
United States of America
Address
Suite 301, 1111 Kane Concourse, Bay Harbor Islands, Florida, 33154
Website
www.fortressbiotech.com
Telephone
1 781 6524500
No of Employees
101
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
FBIO (NASD)
Revenue (2024)
$57.7M
-31.8%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
24.1%
(2024 vs 2023)
Market Cap*
$83.8M
Net Profit Margin (2024)
XYZ
-11.2%
(2024 vs 2023)
* As of and is in US$
Fortress Biotech Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Marketed | Emrosi |
| Unloxcyt | Qbrexza |
| Qbrexza | Accutane |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | New Products/Services | In March, the company's subsidiary Journey Medical Corp, announced the launch of Emrosi for the treatment of Rosacea. |
| 2025 | Contracts/Agreements | In March, the company entered into an agreement with Partex NV to accelerate asset identification and evaluation using proprietary AI platform. |
| 2025 | Regulatory Approval | In January, the company and Cyprium Therapeutics, Inc. accepted a review of the application by the US Food and Drug Administration for CUTX-101 (Copper Histidinate) for the treatment of Menkes disease, a rare X-linked recessive pediatric disease caused by gene mutations of the copper transporter ATP7A. |
Competitor Comparison
| Key Parameters | Fortress Biotech Inc | Sun Pharmaceutical Industries Ltd | Almirall SA | Mayne Pharma Group Ltd | Arcutis Biotherapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | India | Spain | Australia | United States of America |
| City | Bay Harbor Islands | Mumbai | Barcelona | Adelaide | Westlake Village |
| State/Province | Florida | Maharashtra | Barcelona | South Australia | California |
| No. of Employees | 101 | 43,000 | 2,084 | 450 | 342 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Lindsay A. Rosenwald, M.D. | Chairman; Chief Executive Officer; President | Executive Board | 2013 | 70 |
| David Jin | Head - Corporate Development; Chief Financial Officer | Senior Management | 2022 | 35 |
| Michael S. Weiss | Vice Chairman - Strategic Development | Executive Board | 2013 | 59 |
| George Avgerinos, Ph.D. | Senior Vice President - Biologics Operations | Senior Management | 2013 | 71 |
| Samuel Berry | Secretary; General Counsel | Senior Management | 2018 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer